Michelle HS Tosin

Dr. Michelle HS Tosin

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
CMCesar Minelli
Cesar Minelli
GLGustavo José Luvizutto
Gustavo José Luvizutto
RCRoberta de Oliveira Cacho
Roberta de Oliveira Cacho
LNLuciana de Oliveira Neves
Luciana de Oliveira Neves
SMSheila Cristina Sayuri Abe Magalhães
Sheila Cristina Sayuri Abe Magalhães
RBRODRIGO BAZAN
RODRIGO BAZAN
The Brazilian Practice Guidelines for Stroke Rehabilitation – Part II, developed by the Scientific Department of Neurological Rehabilitation of the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, in Portuguese), focuses on specific rehabilitation techniques to aid recovery from impairment and disability after stroke. As in Part I, Part II is also based on recently available evidence from randomized controlled trials, systematic reviews, meta-analyses, and other guidelines. Part II covers disorders of communication, dysphagia, postural control and balance, ataxias, spasticity, upper limb rehabilitation, gait, cognition, unilateral spatial neglect, sensory impairments, home rehabilitation, medication adherence, palliative care, cerebrovascular events related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the future of stroke rehabilitation, and stroke websites to support patients and caregivers. Our goal is to provide health professionals with more recent knowledge and recommendations for better rehabilitation care after stroke.

4 December 2024 in Movement Disorders
Verified
Journal Article
Open access
OGOta Gál
Ota Gál
MBMarjolaine Baude
Marjolaine Baude
TDThierry Deltombe
Thierry Deltombe
AEAlberto Esquenazi
Alberto Esquenazi
JGJean‐Michel Gracies
Jean‐Michel Gracies
TGthe members of the MDS Clinical Outcome Assessments Scientific Evaluation Committee and MDS Spasticity Study group
the members of the MDS Clinical Outcome Assessments Scientific Evaluation Committee and MDS Spasticity Study group
Background: Spasticity is a common feature in patients with disruptions in corticospinal pathways. However, the term is used ambiguously. Here, spasticity is defined as enhanced velocity‐dependent stretch reflexes and placed within the context of deforming spastic paresis encompassing other forms of muscle overactivity.Objective: This scoping review aims at evaluating the clinimetric quality of clinical outcome assessments (COAs) for spasticity across different pathologies and to make recommendations for their use.Methods: A literature search was conducted to identify COAs used to assess spasticity. An international expert panel evaluated the measurement properties in the included COAs. Recommendations were based on the MDS‐COA program methodology based on three criteria: if the COA was (1) applied to patients with spastic paresis, (2) used by others beyond the developers, and (3) determined to be reliable, valid, and sensitive to change in patients with spasticity.Results: We identified 72 COAs of which 17 clinician‐reported outcomes (ClinROs) and 6 patient‐reported outcomes (PROs) were reviewed. The Tardieu Scale was the only ClinRO recommended for assessing spasticity. One ClinRO—Composite Spasticity Index—and two PROs—Spasticity 0–10 Numeric Rating Scale and 88‐Item Multiple Sclerosis Spasticity Scale—were recommended with caveats. The Ashworth‐derived COAs were excluded after evaluation due to their focus on muscle tone rather than spasticity, as defined in this review.Conclusions: The Tardieu Scale is recommended for assessing spasticity, and two PROs are recommended with caveats. Consistent terminology about the various types of muscle overactivity is necessary to facilitate their assessment and treatment. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 June 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
CMCesar Minelli
Cesar Minelli
RBRODRIGO BAZAN
RODRIGO BAZAN
MPMarco Túlio Araújo Pedatella
Marco Túlio Araújo Pedatella
LNLuciana de Oliveira Neves
Luciana de Oliveira Neves
RCRoberta de Oliveira Cacho
Roberta de Oliveira Cacho
SMSheila Cristina Ouriques Martins
Sheila Cristina Ouriques Martins
The Guidelines for Stroke Rehabilitation are the result of a joint effort by the Scientific Department of Neurological Rehabilitation of the Brazilian Academy of Neurology aiming to guide professionals involved in the rehabilitation process to reduce functional disability and increase individual autonomy. Members of the group participated in web discussion forums with predefined themes, followed by videoconference meetings in which issues were discussed, leading to a consensus. These guidelines, divided into two parts, focus on the implications of recent clinical trials, systematic reviews, and meta-analyses in stroke rehabilitation literature. The main objective was to guide physicians, physiotherapists, speech therapists, occupational therapists, nurses, nutritionists, and other professionals involved in post-stroke care. Recommendations and levels of evidence were adapted according to the currently available literature. Part I discusses topics on rehabilitation in the acute phase, as well as prevention and management of frequent conditions and comorbidities after stroke.

29 May 2020 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MTMichelle HS Tosin
Michelle HS Tosin
CGChristopher G. Goetz
Christopher G. Goetz
SLSheng Luo
Sheng Luo
DCDongrak Choi
Dongrak Choi
GSGlenn T. Stebbins
Glenn T. Stebbins

13 February 2024 in Neurology
Verified
Journal Article
Open access
MTMichelle HS Tosin
Michelle HS Tosin
CGChristopher G. Goetz
Christopher G. Goetz
GSGlenn T. Stebbins
Glenn T. Stebbins
To effectively customize Parkinson disease (PD) programs, it is important to incorporate the "individual's voice" and have a thorough understanding of the symptom priorities of people with PD (PwP) and care partners (CP). In this convergent integrated mixed-method systematic review, we aimed to analyze qualitative and quantitative evidence of PD motor and nonmotor symptoms affecting health-related quality of life (HRQOL) in PwP and CP, comparing priorities across different levels of disease severity. We searched MEDLINE, PsycINFO, Web of Science, Embase, and Scopus; ProQuest Dissertations and Theses Global; and the Michael J. Fox Foundation Data Resources for studies published up to June 29, 2022. We included qualitative, quantitative, and mixed-method studies investigating PD symptom priorities among PwP and CP. We critically appraised eligible studies for methodological quality using the Mixed-Methods Appraisal Tool. Derived terms were mapped and coded according to thematic attribution. Independent syntheses of qualitative and quantitative evidence and transformation of quantitative data into qualitative formats were performed. Of the 7,716 identified studies, we included 70 that provided qualitative (n = 13), quantitative (n = 53), and mixed (n = 4) evidence. We included 604 mapped terms representing 11 PwP-identified and CP-identified motor and nonmotor symptom categories. Across all PD stages, both PwP and CP considered 5 domains more affecting their HRQOL, namely: "motor functionality," "mood," "cognition," "gait, balance, posture, and falls," and "nighttime sleep disorders." In early disease, PwP and CP considered "mood" the domain that most affected their HRQOL. In advanced PD, PwP considered "pain" the domain that most affects their HRQOL, while CP considered "psychiatric symptoms." The domain "gait, balance, posture, and falls" was equally considered by both PwP and CP as the second domain that most affects their HRQOL in the advanced stage of PD. The ranking of the priority of symptoms is largely shared by PwP and CP, and motor symptom priorities dominate the full disease spectrum. However, the nonmotor symptom priorities shift according to the disease severity stage. Tailored care and research require that providers consider these shifting priorities and incorporate the "individual's voice" into treatment decisions.

27 March 2025 in Movement Disorders
Verified
Journal Article
Open access
OBOndrej Bezdicek
Ondrej Bezdicek
RBRoberta Biundo
Roberta Biundo
SBSarai Boelema
Sarai Boelema
DCDavide Maria Cammisuli
Davide Maria Cammisuli
BCBrenna Cholerton
Brenna Cholerton
TCthe members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
the members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
Background: Cognitive impairment in Parkinson's disease (PD) is a key non‐motor complication during the disease course.Objectives: A review of detailed cognitive instruments to detect mild cognitive impairment (PD‐MCI) or dementia (PDD) is needed to establish optimal tests that facilitate diagnostic accuracy.Methods: We performed a systematic literature review of tests that assess memory, language including premorbid intelligence, and visuospatial domains (for tests of attention and executive functions see accompanying review) to determine suitability to assess cognition in PD. Based on in‐depth scrutiny of psychometric and other relevant clinimetric properties, tests were rated as “recommended,” “recommended with caveats,” “suggested,” or “listed” by the International Parkinson and Movement Disorder Society (IPMDS) panel of experts according to the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee guidelines.Results: We included 39 tests encompassing 48 outcome measures. Seven tests (different versions or subtests of the test counted once) were recommended, including four for memory, one for visuospatial domains, one for language (including three measures), and one for estimated premorbid intelligence. Furthermore, 10 tests (12 measures) were “recommended with caveats,” 11 were “suggested,” and 11 (15 measures) were “listed.”Conclusions: Recommended neuropsychological tests in memory, visuospatial functions, and language are proposed to guide the assessment of cognitive impairment and its progression in PD‐MCI and PDD, and for use in clinical trials to stratify participants or as outcome measures. Novel measures being developed will need extensive validation research to be “recommended.” © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.